- Firebrick Pharma (FRE) recruits the first patient under its phase three trial for its Nasodine Nasal Spray as a treatment for the common cold
- The trial will recruit up to 450 adult participants with early cold symptoms to achieve a target treatment population of 196 subjects
- The primary endpoint will be the impact of Nasodine on overall cold severity which will be measured using the Global Severity Score from the WURSS-21 cold severity survey
- Firebrick currently has two major clinical trials underway with results expected later in the year
- Firebrick ends the day 1.23 per cent in the red with shares trading at 40 cents
Firebrick Pharma (FRE) has recruited the first patient under its phase three trial for its Nasodine Nasal Spray as a treatment for the common cold.
The trial will recruit up to 450 adult participants with early cold symptoms to achieve a target treatment population of 196 subjects.
It will be double-blinded, randomised and placebo-controlled, titled “Confirmatory Phase III study of Nasodine Nasal Spray (povidone-iodine 0.5 per cent) as a symptomatic treatment for early stage common cold in the natural setting.”
The primary endpoint will be the impact of Nasodine on overall cold severity, which will be measured using the Global Severity Score from the WURSS-21 cold severity survey.
The trial will be undertaken at three sites across Australia and two in South Africa with patients already recruited in Adelaide.
Firebrick currently has two major clinical trials underway with results expected later in the year.
“This is the second Phase 3 trial for Nasodine and we are excited to take what we believe will be the final step towards commercialisation of Nasodine in Australia, and to lay the pathway for international approval and distribution,” Executive Chairman Dr Peter Molloy said.
“Nasodine is a first-in-class nasal spray medicine that actually targets the viral cause of the common cold, where colds start — in the nose.”
Firebrick has ended the day 1.23 per cent in the red with shares trading at 40 cents.